



# Market Announcement

11 July 2018

---

## MGC Pharmaceuticals Ltd – Trading Halt

### Description

The securities of MGC Pharmaceuticals Ltd (the 'Company') will be placed in trading halt at the request of the Company, pending the release of an announcement by the Company. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Friday, 13 July 2018 or when the announcement is released to the market.

---

<b>Security Code:</b>	MXC
-----------------------	-----

---

### Issued by

**Dawn James**

Senior Adviser, Listings Compliance (Perth)

11 July 2018

Australian Securities Exchange  
Level 40, Central Park  
152-158 St Georges Tce  
Perth WA 6000

Via email: [tradinghaltspert@asx.com.au](mailto:tradinghaltspert@asx.com.au)

Dear Sir/Madam

The Directors of MGC Pharmaceuticals Ltd (the "Company") request that the Company's securities be placed in a voluntary trading halt immediately in accordance with ASX Listing Rule 17.1, pending the release of an announcement by the Company regarding the Good Manufacturing Practice (GMP) certification approval process being sought by the Company to commence production at its European Medicinal Cannabis Laboratory and Extraction Facility of pharmaceutical grade medicinal cannabis products.

The Company requests that the trading halt end on the earlier of the commencement of normal trading on Friday 13 July 2018, or when the announcement referred to above is released to the market.

The Company is not aware of any reason why the trading halt should not be granted, nor of any other information necessary to inform the market about the trading halt, and the Company confirms that the request for a trading halt is material.

Yours faithfully



Brett Mitchell  
Executive Chairman